EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Hyperuricemia, A new cardiovascular risk

Masanari Kuwabara, Ichiro Hisatome, Ryusuke Ae, Koki Kosami, Yuhei Aoki, Ana Andres-Hernando, Mehmet Kanbay, Miguel A Lanaspa

Nutrition, Metabolism and Cardiovascular Diseases · 2025-03 · 35 (3) · 103796

DOI: 10.1016/j.numecd.2024.103796 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2025-03. Verfasst von Masanari Kuwabara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health, Center for Community Medicine, Jichi Medical University, Tochigi, Japan; Division of Cardiovascular Medicine, Department o…. Hauptthemen laut MEDLINE: Hyperuricemia, Cardiovascular Diseases, Uric Acid, Gout Suppressants. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Gout and Uric Acid Foundation, Gout and Uric Acid Research Foundation of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Hyperuricemia is strongly linked to increased cardiovascular risk, including hypertension, coronary artery disease, arrythmia, and heart failure. Uric acid, as the end-product of purine metabolism, plays a critical role in cellular processes, but elevated levels can drive inflammation and oxidative stress. This review aims to emphasize the robust association between hyperuricemia and cardiovascular diseases, exploring whether uric acid-lowering therapies can mitigate cardiovascular events and improve patient outcomes. METHODS AND RESULTS: A comprehensive review of PubMed sources was conducted, underscoring the significant link between high uric acid levels and cardiovascular events, particularly in patients with gout. Gender differences were observed, where premenopausal women have lower uric acid levels, likely due to hormonal effects, suggesting the potential need for gender-specific definitions in assessing cardiovascular risk. Epidemiological studies demonstrate a consistent correlation between hyperuricemia and adverse cardiovascular outcomes. However, interventional trials using xanthine oxidase inhibitors, such as allopurinol and febuxostat, have shown mixed results regarding their impact on reducing cardiovascular events. Additionally, emerging evidence suggests a "xanthine oxidase withdrawal syndrome" upon discontinuation of these therapies, highlighting the need for cautious management. CONCLUSION: The strong association between elevated uric acid levels and cardiovascular diseases is well-documented. While lowering uric acid shows potential for reducing cardiovascular risk, current evidence from interventional trials remains inconclusive. Future research should focus on patient-specific therapeutic strategies, particularly for those at high cardiovascular risk with hyperuricemia and/or gout, to better define the benefits of targeted treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaCardiovascular DiseasesUric AcidGout SuppressantsHumansRisk AssessmentBiomarkersFemaleMaleHeart Disease Risk FactorsXanthine OxidaseTreatment OutcomePrognosisEnzyme InhibitorsProtective Factors

Stichwörter der Autor:innen

Asymptomatic hyperuricemiaCardiovascular diseaseGoutRisk factorUric acid

Substanzen

Uric AcidBiomarkersGout SuppressantsXanthine OxidaseEnzyme Inhibitors

Autor:innen und Institutionen

  • Division of Public Health, Center for Community Medicine, Jichi Medical University, Tochigi, Japan; Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University Tochigi, Japan; Department of Car…
  • Department of Cardiology, NHO Yonago Medical Center, Tottori, Japan.
  • Division of Public Health, Center for Community Medicine, Jichi Medical University, Tochigi, Japan.
  • Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Division of Endocrinology, Metabolism and Diabetes, School of Medicine, University of Colorado Denver, Aurora, CO, USA.
  • Division of Nephrology, Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.

Förderung

  • Japan Society for the Promotion of Science
  • Gout and Uric Acid Foundation
  • Gout and Uric Acid Research Foundation of Japan

Zitieren

APA

Kuwabara, M., Hisatome, I., Ae, R., Kosami, K., Aoki, Y., Andres-Hernando, A., Kanbay, M., & Lanaspa, M. A. (2025). Hyperuricemia, A new cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases, 35(3), 103796. https://doi.org/10.1016/j.numecd.2024.103796

Vancouver

Kuwabara M, Hisatome I, Ae R, Kosami K, Aoki Y, Andres-Hernando A, et al. Hyperuricemia, A new cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases. 2025;35(3):103796. doi:10.1016/j.numecd.2024.103796

BibTeX
@article{Kuwabara2025,
  author = {Kuwabara, Masanari and Hisatome, Ichiro and Ae, Ryusuke and Kosami, Koki and Aoki, Yuhei and Andres-Hernando, Ana and Kanbay, Mehmet and Lanaspa, Miguel A},
  title = {Hyperuricemia, A new cardiovascular risk},
  journal = {Nutrition, Metabolism and Cardiovascular Diseases},
  year = {2025},
  volume = {35},
  number = {3},
  pages = {103796},
  doi = {10.1016/j.numecd.2024.103796}
}
Kostenlos starten →